Results 51 to 60 of about 3,606,854 (303)

ComTarget: Small-Molecule Target Prediction with Combinatorial Modeling

open access: yesPharmaceuticals
Background: Identifying potential targets for bioactive compounds is crucial for elucidating the mechanisms of action and drug development. Methods: This study presents ComTarget, a computational tool that integrates 3D molecular shape similarity ...
Yuzhu Li   +6 more
doaj   +1 more source

Neurochemical Endpoints to Inform Early‐Stage Trials of Spinocerebellar Ataxia 2 and 3 in a Multisite Setting

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Neurochemical levels measured by brain MR spectroscopy (MRS) have been proposed as endpoints for clinical trials in early‐stage spinocerebellar ataxia (SCA) trials. We tested their trial‐readiness by quantifying neurochemicals in three affected brain regions in early‐stage cohorts of SCA2 and SCA3, examining their reproducibility in ...
James M. Joers   +19 more
wiley   +1 more source

The menopause and the Pharmaceutical Industry

open access: yesJournal of Psychosomatic Obstetrics & Gynecology, 1997
Since 1975, pharmaceutical firms specializing in the endocrine field have made a vigorous attempt to develop a large market in estrogens for the long-term treatment of postmenopausal women. The success of the contraceptive 'pill' had demonstrated the commercial attractiveness of developing products for an essentially healthy population.
openaire   +2 more sources

Effects of Add‐On Icosapent Ethyl With Standard Treatment on Functional Outcomes and Inflammatory Biomarkers in Acute Ischemic Stroke: A Blinded Randomized Controlled Trial

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Background Ischemic stroke, a major cause of mortality and long‐term disability, results from the abrupt cessation of cerebral blood flow due to vascular occlusion or rupture. Icosapent Ethyl (EPA‐EE), approved for hypertriglyceridemia, has anti‐inflammatory and antithrombotic properties that may lessen ischemic damage.
Mitra Mahmoudi Meymand   +5 more
wiley   +1 more source

Global Rather Than Vertical‐Selective Saccadic Abnormalities in Progressive Supranuclear Palsy

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective To test whether vertical saccades are preferentially affected in Progressive Supranuclear Palsy (PSP). Methods PSP patients (n = 24) were compared to age‐matched controls (n = 94) and two degenerative groups (Alzheimer's disease, n = 20; Lewy body disease, n = 50).
Duy Duan Nguyen   +6 more
wiley   +1 more source

Intracerebral Hemorrhage Induces Monocyte TNF Signaling in Patients That Is Suppressed by BAF312

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Intracerebral hemorrhage (ICH) causes high morbidity and mortality, with neurotoxic inflammation driven by infiltrating monocytes. This study is an in‐depth longitudinal examination of the immune response during the first week of ICH in the presence and absence of the immunomodulatory drug BAF312 (Siponimod).
Jonathan Howard DeLong   +10 more
wiley   +1 more source

R&D, Within and Between Patent Competition in the Pharmaceutical Industry [PDF]

open access: yes, 2013
We analyse the consequences of the increasing complexity of R&D on within- and between-patent competition in the pharmaceutical industry. The intensity of competition is measured by jointly considering the timing from market launch to patent expiry, the
Magazzini, Laura   +2 more
core  

Innovation in the pharmaceutical industry [PDF]

open access: yesBMJ, 1994
The pharmaceutical industry today is operating in an environment whose main feature is an unprecedented pace of change. In most markets the rising costs of health care are of increasing concern, and the medicines bill is being targeted for savings. New constraints are limiting the medicines that can be used and paid for in the system.
openaire   +2 more sources

Evaluation of the Pharmaceutical Industry Investment Program [PDF]

open access: yes
With the expiry of the Pharmaceutical Industry Investment Program (PIIP) in 2004, the Commission was asked to conduct an evaluation of the program’s rationale, effectiveness and efficiency. The study commenced in August 2002.
Productivity Commission
core  

Physician‐Scientist Pipeline for Pediatric Rheumatology: The Current Landscape and Future Perspectives

open access: yesArthritis Care &Research, EarlyView.
Over the past 50 years, the science of pediatric rheumatology has grown exponentially due to an expansion in the understanding of complex rheumatic conditions and a surge in novel targeted therapeutics. Physician‐scientists in the field of pediatric rheumatology have played major roles in these advancements that have improved the care of children ...
Ekemini A. Ogbu   +2 more
wiley   +1 more source

Home - About - Disclaimer - Privacy